AU3091597A - Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca) - Google Patents

Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)

Info

Publication number
AU3091597A
AU3091597A AU30915/97A AU3091597A AU3091597A AU 3091597 A AU3091597 A AU 3091597A AU 30915/97 A AU30915/97 A AU 30915/97A AU 3091597 A AU3091597 A AU 3091597A AU 3091597 A AU3091597 A AU 3091597A
Authority
AU
Australia
Prior art keywords
prevention
treatment
fudca
colorectal cancer
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30915/97A
Other languages
English (en)
Inventor
Leonhard Robert Capuano
Joyce Corey Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU3091597A publication Critical patent/AU3091597A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU30915/97A 1996-05-23 1997-05-22 Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca) Abandoned AU3091597A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1820296P 1996-05-23 1996-05-23
US60018202 1996-05-23
PCT/EP1997/002632 WO1997044043A1 (en) 1996-05-23 1997-05-22 Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)

Publications (1)

Publication Number Publication Date
AU3091597A true AU3091597A (en) 1997-12-09

Family

ID=21786767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30915/97A Abandoned AU3091597A (en) 1996-05-23 1997-05-22 Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)

Country Status (10)

Country Link
US (1) US6426340B1 (enExample)
EP (1) EP0906106B1 (enExample)
JP (2) JP2000510858A (enExample)
AT (1) ATE394107T1 (enExample)
AU (1) AU3091597A (enExample)
CA (1) CA2253593C (enExample)
DE (1) DE69738667D1 (enExample)
ES (1) ES2306459T3 (enExample)
PT (1) PT906106E (enExample)
WO (1) WO1997044043A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790123B2 (ja) * 1998-07-24 2011-10-12 ヨー、セオ、ホン 胆汁酸を有する透明水溶液型製剤の調剤
US6677319B1 (en) * 1998-08-06 2004-01-13 Wolfgang Stremmel Phosphatidylcholine as medication with protective effect large intestinal mucosa
KR100621281B1 (ko) * 1999-09-28 2006-09-13 파나세아 바이오테크 리미티드 니메설라이드를 포함하는 방출제어형 조성물
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
CA2503811A1 (en) * 2002-11-01 2004-05-21 James Kaput Identification of diet-regulated disease-associated genes
US20090074785A1 (en) * 2007-01-16 2009-03-19 Smith Jeffrey W Compositions and methods for treatment of colorectal cancer
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
LT2637668T (lt) 2010-11-04 2016-09-12 Albireo Ab Ibat inhibitoriai kepenų ligoms gydyti
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
MY209425A (en) 2018-06-20 2025-07-08 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HRP20230039T1 (hr) 2019-02-06 2023-06-09 Albireo Ab Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8825526D0 (en) * 1988-11-01 1988-12-07 Enzymatix Ltd Diagnosis
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps

Also Published As

Publication number Publication date
EP0906106A1 (en) 1999-04-07
PT906106E (pt) 2008-08-07
JP2000510858A (ja) 2000-08-22
DE69738667D1 (de) 2008-06-19
EP0906106B1 (en) 2008-05-07
CA2253593A1 (en) 1997-11-27
CA2253593C (en) 2008-07-08
JP2010059175A (ja) 2010-03-18
ES2306459T3 (es) 2008-11-01
ATE394107T1 (de) 2008-05-15
US6426340B1 (en) 2002-07-30
WO1997044043A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
AU3091597A (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
CA2350538A1 (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
WO1998051294A3 (en) Method and composition for treating cancers
IL148127A0 (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
AU7239996A (en) Inhibition of tumor necrosis factor alpha
AU7500794A (en) Novel use of dexmedetomidine
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
HK1043303A1 (zh) 阿朴嗎啡在用於治療男性器質性勃起功能障礙的藥物的製備中的應用
MY121623A (en) Methods of preventing breast cancer.
CA2326528A1 (en) Cholesterol sulfate compositions for artificial skin tanning
CA2116829A1 (en) Use of a pregnane derivative
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2000029012A8 (en) Methods of alleviating cancer symptoms
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
PL328123A1 (en) Derivatives of banzo[c]quinolysine and method of obtaining them
CA2098593A1 (en) Treatment method for cancer
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
AU2002310920A1 (en) Pharmaceutical compositions comprising ascomycin
WO2001037784A3 (en) Method for preventing irinotecan induced diarrhea
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
WO2001040241A3 (en) 6-o-alkyl-2-nor-2-substituted ketolide derivatives